Tuesday, January 8, 2019
Voyager Therapeutics price target lowered to $23 from $32 at BTIG
BTIG analyst Thomas Shrader lowered his price target on Voyager Therapeutics to $23 after the company’s announcement yesterday about increasing the size of its RESTORE-1 Phase 2 trial for VY-AADC in Parkinson’s Disease following FDA feedback. The analyst notes that the “final answer” on the trial represents “about a year delay” in the development of VY-ADCC, but keeps his Buy rating on the stock, saying he remains positive on Voyager Therapeutics investment story.
https://thefly.com/landingPageNews.php?id=2845501
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.